Alkem Laboratories announced an Amendment cum Supplemental Agreement dated February 13, 2026, concerning its subsidiary, Enzene Biosciences. The amendment facilitates the allotment of securities to F-Prime Capital and ERVI Healthcare via private placement. This restructuring involves the infusion of ₹26.16 crore and adjusts the post-allotment shareholding structure of Enzene among the key parties involved.
Shareholders’ Agreement Amendment Detailed
Alkem Laboratories Ltd. has informed the exchanges regarding an Amendment cum Supplemental Agreement executed on February 13, 2026. This agreement involves the Company, Enzene Biosciences Limited (a subsidiary, referred to as “Enzene”), Eight Roads Ventures, F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”), and ERVI Healthcare IV Holdings Limited (“ERVI Healthcare”).
The purpose of this amendment is threefold: (a) to formalize the allotment of securities by Enzene to F-Prime Capital and ERVI Healthcare via preferential private placement; (b) to ensure ERVI Healthcare adheres to the existing Shareholders’ Agreement terms; and (c) to amend specific provisions within that original agreement.
Investment and Share Allotment Details
A significant term of this arrangement is the capital infusion totaling Rs. 26,16,25,003/-. This capital will be used to subscribe for securities in Enzene:
- F-Prime Capital will subscribe to 1,30,451 Series B CCPS at a price of Rs. 468.60/- per share (including a premium of Rs. 458.60/-).
- ERVI Healthcare will subscribe to 4,27,851 Series B CCPS and 10 Equity Shares, also at a price of Rs. 468.60/- per share (including a premium of Rs. 458.60/- for the CCPS).
The issuance price for all shares (CCPS and Equity) is set at Rs. 468.60/- per unit, with a face value of Rs. 10/- for the CCPS and Equity Shares.
Post-Allotment Shareholding in Enzene
Following the allotment, the updated total share capital structure of Enzene (on a fully diluted basis) is summarized below:
| Entity | % of Total Share Capital (Post Allotment) |
|---|---|
| Alkem | 88.99% |
| Eight Roads Ventures | 5.42% |
| F-Prime Capital | 1.87% |
| ERVI Healthcare | 0.71% |
Transaction Classification
The Company has explicitly stated that this transaction does not fall within the purview of related party transactions. Furthermore, the change is not expected to have any material impact on the management or control of Alkem Laboratories itself, as Enzene remains a subsidiary.
Source: BSE
